Tiziana Life Sciences Ltd
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -12.1% | +91.5% | -26.1% | -22.9% | +29.1% | +25.2% | -16.9% | -8.2% | -8.2% | -31.7% | -12.7% | -41.0% | -38.7% | -84.6% | +31.3% | +1,852.4% | +276.0% | -45.4% | -63.7% | +277.3% | -73.8% | +3,808.0% | -30.9% | -45.8% | -54.0% | -7.4% | +1.9% | |
| – | -68.7% | +1,005.1% | -45.4% | -52.4% | +118.3% | +30.7% | -35.1% | -30.4% | +9.2% | -76.8% | -24.9% | +11.4% | +149.8% | -94.2% | +366.7% | +1,852.4% | +276.0% | -45.7% | -63.9% | +280.6% | -83.4% | +6,034.3% | -30.6% | -50.1% | -69.8% | +2.3% | +13.9% | |
| – | -72.1% | +1,287.3% | -49.5% | -99.4% | +14,128.6% | -22.6% | +22.0% | -46.0% | +15.7% | -95.7% | +20.0% | +134.1% | -53.0% | -87.9% | +1,425.0% | +3,614.8% | +292.9% | -47.2% | -99.0% | +10,930.9% | -97.1% | +42,922.2% | -35.9% | -57.0% | -93.5% | +214.8% | +7.7% | |
| – | -72.1% | +1,414.6% | -53.8% | -50.6% | +83.4% | -22.6% | +22.0% | -46.0% | +15.7% | -95.7% | +20.0% | +134.1% | +547.7% | -95.6% | +280.0% | +2,881.6% | +292.9% | -47.2% | -99.0% | +10,930.9% | -97.1% | +42,922.2% | -35.9% | -57.0% | -93.5% | +214.8% | +7.7% | |
| – | – | – | – | – | – | – | -83.9% | +54.0% | -2.0% | -66.6% | -39.5% | +48.0% | – | – | – | – | +172.3% | -65.6% | +1,556.0% | -16.6% | -0.6% | +194.5% | +39.3% | +11.2% | +3.3% | -39.0% | +15.3% | |
| – | – | – | – | – | – | – | +300.0% | +400.0% | -65.0% | +314.3% | +31.0% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -13.1% | -71.2% | +6,171.4% | -18.0% | -95.3% | +2,188.2% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +10.1% | -13.8% | +2.4% | -0.1% | -2.0% | +20.0% | -1.1% | +4.3% | -13.9% | -59.2% | +97.0% | -72.7% | – | – | – | – | – | – | – | – | – | – | -2.0% | – | – | – | – | |
| – | -12.6% | +34.7% | -26.4% | -1.1% | -21.4% | +113.1% | +2.8% | +18.4% | -36.9% | +38.7% | -19.3% | -19.5% | -76.0% | +36.0% | +100.0% | +151.1% | +9.2% | +132.8% | +102.3% | +81.8% | -6.3% | +38.1% | -8.8% | -8.5% | -3.7% | +10.5% | +55.7% | |
| – | -12.6% | +34.7% | -26.4% | -1.1% | -21.4% | +113.1% | +2.8% | +2.3% | -42.7% | +49.4% | -22.9% | -0.2% | -76.0% | +36.0% | +100.0% | +151.1% | +9.2% | +132.8% | +102.3% | +91.9% | -17.3% | +43.1% | -5.4% | -11.7% | -1.9% | +12.4% | +52.5% | |
| – | – | – | – | – | – | – | -23.8% | -6.5% | -29.2% | +2.0% | -5.8% | – | – | – | – | -10.4% | +4.9% | +4.2% | +4.0% | +32.2% | +183.8% | +162.7% | -41.3% | -91.0% | +13.1% | -23.2% | +109.4% | |
| – | -7.9% | -49.3% | +1.1% | -0.6% | -20.2% | +198.4% | +0.3% | +32.7% | -25.1% | +42.6% | -17.0% | +11.7% | -84.3% | +40.9% | -79.8% | +155.7% | +391.2% | +286.3% | +128.3% | +38.7% | +5.6% | -17.0% | +30.9% | +12.6% | -16.6% | +34.9% | +28.5% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -11.9% | +101.9% | -26.1% | -25.6% | +37.3% | +17.0% | -20.3% | -14.1% | +0.5% | -45.1% | -9.5% | -50.2% | -13.1% | -107.6% | – | – | +378.6% | -61.0% | -150.8% | – | -906.8% | – | -9.7% | -52.6% | -71.7% | -28.9% | -98.7% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -369.6% | – | – | – | – | – | – | – | – | |
| – | -3.3% | -1.3% | +27.8% | +119.9% | +103.2% | +18.3% | +47.4% | +55.6% | +39.2% | +85.1% | +216.7% | +238.1% | +87.2% | +39.0% | +1,154.5% | -50.0% | +718.6% | +13.7% | +9.9% | +16.7% | +0.0% | -28.7% | +0.6% | +3.7% | +0.0% | +5.1% | +10.9% |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.